EU/3/01/084

Table of contents

About

On 6 February 2002, orphan designation (EU/3/01/084) was granted by the European Commission to Pharmion Limited, United Kingdom, for azacitidine for the treatment of myelodysplastic syndromes.

The sponsorship was transferred to Celgene Europe Limited, United Kingdom, in October 2008.

Azacitidine in treatment of myelodysplastic syndromes has been authorised in the EU as Vidaza since 17 December 2008.

The sponsorship was transferred to Celgene Europe B.V., The Netherlands, in June 2018.

Key facts

Active substance
azacitidine
Medicine name
Vidaza
Disease / condition
Treatment of myelodysplastic syndromes
Date of decision
05/02/2002
Outcome
Positive
Orphan decision number
EU/3/01/084

Sponsor's contact details

Celgene Europe B.V.
Winthontlaan 6N
3526 KV Utrecht
The Netherlands
Tel. +31 3028 44547
E-mail: medinfo.intl@celgene.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;

How useful was this page?

Add your rating